



ALK's CEO Jens Bager steps down

February 22, 2016

Copenhagen, 2016-02-22 17:07 CET (GLOBE NEWSWIRE) --

ALK ([ALKB:DC](#) / OMX: ALK B / AKABY / AKBLF) today announced that as of 22 February 2016, Jens Bager will resign as President and CEO.

The search for a new CEO will be initiated immediately. In the meantime, Steen Riisgaard will be Chairman of the Board with extended operational responsibilities, and will in his role act as day-to-day leader of the company.

"The Board assesses that now is a good moment to look for a new CEO. We have therefore made an agreement with Jens Bager for him to step down from his position. We will look for a new CEO with relevant experiences and competences to support the global commercialisation of ALK's portfolio of evidence-based products targeting both allergic rhinitis and asthma," says Steen Riisgaard.

"For 16 years, Jens has led ALK to its present position as world leader within allergy immunotherapy. ALK has a strong foundation for growth and the company has reached several important milestones including the approval of the house dust mite SLIT-tablet ACARIZAX® in 11 European countries and Japan (marketed as MITICURE™). Moreover, ALK has established a portfolio of promising partnerships to support its transformation to become a truly global company. We want to thank Jens for these achievements," says Steen Riisgaard.

Jens Bager comments on the change: *"I take great pride in the company that I now hand over to a new CEO. All strategic and financial indications are positive and point in the right direction. That is why the timing of this change is right in relation to expanding my board career, and I will now pursue this opportunity."*

There will be no other changes to ALK's Board of Management consisting of Henrik Jacobi, EVP Research & Development, Flemming Pedersen, CFO, Søren Niegel, EVP Commercial Operations and Helle Skov, EVP Product Supply.

ALK-Abelló A/S

Audio cast

Tomorrow morning, ALK hosts a conference call at 08.30 a.m. (CET) at which Chairman of the Board of Director Steen Riisgaard together with members of Board of Management will answer questions in relation to this announcement. The call will be audio cast on www.alk-abello.com/investor. Participants in the conference call are kindly requested to call in before 8.25 a.m. (CET). Danish participants should call in on tel. 7022 3500 and international participants should call in on tel. +44 (0) 20 7572 1187 or +1 646 722 4972. Please use the following participant pin code: 78521931#.

For further information:

Chairman of the Board of Directors and CEO ad interim
Steen Riisgaard, tel. +45 4574 7576

Investor Relations and media:

Per Plotnikof, tel. +45 4574 7527, mobile +45 2261 2525

About ALK

ALK is a research-driven global pharmaceutical company focusing on allergy prevention, diagnosis and treatment. ALK is a world leader in allergy immunotherapy — a treatment of the underlying cause of allergy. The company has approximately 1,900 employees with subsidiaries, production facilities and distributors worldwide. ALK has entered into partnership agreements with MSD (known as Merck (NYSE: MRK) in the USA and Canada) Torii, Abbott, and Seqirus to commercialise sublingual allergy immunotherapy tablets in North America, Japan, Russia, South-East Asia,

Australia and New Zealand, respectively. The company is headquartered in Hørsholm, Denmark, and listed on NASDAQ Copenhagen. Find more information at www.alk.net.